Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (CLP)

Personalis, Inc. has extended its exclusive commercialization agreement with Tempus AI to include colorectal cancer (CRC), building on its existing focus in breast, lung, and immunotherapy monitoring. The deal centers on NeXT Personal, an ultra-sensitive, tumor-informed minimal residual disease (MRD) test designed to detect cancer recurrence earlier and more accurately. Backed by interim data from the VICTORI study presented at AACR 2025, the collaboration now runs through 2029 with exclusivity across all four indications until 2028. With Tempus’ reach to over 50% of U.S. oncologists, the expanded alliance aims to accelerate adoption of MRD testing in colorectal cancer — affecting over 150,000 Americans annually — and support Personalis’ broader reimbursement and market leadership goals.